

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Jan 2, 2022




RESPIRATORY PATHOGEN PANEL Jan 2, 2022 Positivity Rate (%)

MONTH	FLU A UnSub	FLU A (H1N1)	2009 H1N1	FLU A H3N2	FLU B	RSV A/B	PARA 1	PARA 2	PARA 3	PARA 4	COR 229E	COR NL63	COR OC43	COR HKU1	META	E/R	Adeno	BOCA	Legio-nella	Chla-mydia	Myco-plasma
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.0	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0
SEP	0.0	0.0	0.0	0.0	0.0	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1
OCT	0.0	0.0	0.0	0.0	0.0	7.8	0.0	1.6	1.2	1.0	0.1	0.0	0.4	0.0	0.3	21.0	1.2	4.0	0.2	0.0	0.0
NOV	0.0	0.1	0.1	0.7	0.0	7.6	0.1	1.5	0.9	1.5	0.2	0.1	0.9	0.0	1.0	18.3	1.4	3.7	0.1	0.0	0.0
DEC	0.0	0.0	0.0	2.7	0.0	4.4	0.0	0.8	1.4	1.4	0.4	0.1	1.6	0.2	2.7	11.4	2.3	4.4	0.2	0.0	0.0


Increased prevalence of viruses: **Rhinovirus, RSV, Boca virus, Parainfluenza 2,3,4, Adeno, Flu A**

SARS-COV-2 ↑					Influenza PCR ↓		RSV PCR ↓		Hologic Aptima	
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % RSVPCR	WI % RSVPCR	IL % COV19	WI % COV19
Jan 2	33.4	24.3	41.5	44.4	1.7	6.9	2.6	3.3	33.6	30.9
Dec 26	26.2	17.0	31.9	31.2	1.9	8	2.7	3.6	20.5	16.4
Dec 19	16.3	12.0	18.4	24.5	3.7	9.6	4.1	2.9	11.0	11.8
Dec 12	12.2	8.5	14.7	20.6	5.1	7.1	5.3	4.0	6.9	10.7
Dec 5	11.1	11.3	13.5	22.7	5.5	5.5	5.1	6.0	6.3	11.6
Nov 28	8.8	10.6	12.8	18.9	3.9	1.8	10.2	9.8	6.1	11.4
Nov 21	5.8	10.3	8.5	20.2	1.9	0.2	14.0	12.0	3.8	9.6
Nov 14	4.7	9.0	7.5	21.7	0.5	0	15.0	15.7	3.8	9.6
Nov 7	3.8	7.4	6.6	17.6	0	0.3	21.4	20.7	3.2	7.8
Oct 31	3.8	6.3	4.8	13.7	0.3	0	20.9	32.2	1.9	7.1
Oct 24	3.7	5.6	5.1	16.7	0	0.2	22.5	30.6	2.2	7.0


ACL SARS-CoV-2 trends up, Flu and RSV positivity rate - trends down



ACL RSV positivity rate - **trends down**




ACL Flu positivity rate – **trends down** (160 Flu pos/4014 samples tested)



ACL SARS-CoV-2 positivity rate - trends up


CDC- Daily COVID-19 cases in US – Dec 15, 2021



CDC SARS-CoV-2 positivity rate - **trends up**

Dec 25, 2021 – SARS-CoV-2 circulating in the US based on Nowcast modeling

(41% Delta ↓, 58.6% Omicron ↑)



** CDC uses **Nowcast** model that estimates more recent proportions of circulating variants (actual sequencing data is typically delayed for 2-3 weeks).

US vaccination status CDC | Data as of: Dec 16, 2021

490,030,849

Vaccines Administered

240,321,022

People who received at least one dose

203,159,327

People who are fully vaccinated*

72.4%


Percentage of the U.S. population that has received at least one dose

61.2%


Percentage of the U.S. population that has been fully vaccinated*

US vaccination vs hospitalization status CDC | Data as of: Dec 8, 2021

Age-Adjusted Rates of COVID-19-Associated Hospitalizations by Vaccine Status in Adults Aged ≥ 18 Years, January–November 2021




Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 3, 2021 – December 25, 2021




CDC Flu positivity rate – trends up 6.2%


CDC Midwest data as of: Dec 18, 2021




2021-22 Influenza Season Week 51 ending Dec 25, 2021



CSF targets positivity rate is 3.8%



The most prevalent GI bacterial target is - (Cryptosporidium 0.9%)



The most prevalent GI viral target are – (Rotavirus and Norovirus– 0.6%)

